Drug Trial Radar · NCT00079274
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,397
Actual
Start
Feb 2004
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- Eastern Cooperative Oncology Group
- First posted
- Mar 10, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial was originally designed to compare three different combination chemotherapy regimens to see how well they work. As of September 1, 2004, the study was expanded to a total of 6 arms (the original 3 arms (A, B, C) and 3 additional arms which were the same as the first 3 but with cetuximab) in treating patients who have undergone surgery for stage III colon cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with monoclonal antibody therapy and giving them after surgery may kill any remaining tumor cells. It was not known at the time this study was developed which combination chemotherapy regimen is more effective after surgery in treating colon cancer. This study had several key changes, based on the results of other phase III trials. As of 6/1/2005, patients no longer received irinotecan on this study and treatment arms B, C, E, and F were discontinued. Patients on arms B and C crossed to arm A. Patients on arms E and F crossed to arm D. Patients on arms C and F who had not gotten to irinotecan continued on arms A and D, respectively. As of 8/18/2008, pre-screening for Kirsten rat sarcoma (KRAS) status was added with mutant KRAS (or KRAS not evaluable) patients put on arm G and wild-type KRAS patients randomized between arm A and arm D. Patients on arm G were treated per physician discretion and followed for disease and survival status. KRAS was determined in a central laboratory and was process for all patients on this study. The primary endpoint of this study was modified on 8/18/2008 to focus on patients having wild-type KRAS tumors. All modifications were approved by the Central Institution Review Board, local Institutional Review Boards, NCI, and the NCCTG Data Safety Monitoring Board.
Conditions
- Adenocarcinoma of the Colon
- Stage III Colon Cancer
Interventions
irinotecan hydrochlorideDrug
Given IV
oxaliplatinDrug
Given IV
leucovorin calciumDrug
Given IV
fluorouracilDrug
Given IV
cetuximabBiological
Given IV
Locally Directed TherapyDrug
Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (Arms A and D: Wild-type KRAS Patients)Time frame: At 3 years
Locations
894 sites in 3 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
Clearview Cancer Institute
Huntsville, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Providence Hospital
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Banner Thunderbird Medical Center
Glendale, Arizona
Banner Desert Medical Center
Mesa, Arizona
Banner Baywood Medical Center
Mesa, Arizona
Banner Good Samaritan Medical Center
Phoenix, Arizona
Western Regional CCOP
Phoenix, Arizona
Phoenix Indian Medical Center
Phoenix, Arizona
Scottsdale Healthcare
Scottsdale, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Highlands Oncology Group-Bentonville
Bentonville, Arkansas
Saint Edward Mercy Medical Center
Fort Smith, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Veteran's Administration Medical Center
Little Rock, Arkansas
Alta Bates Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center
Burbank, California
Mills - Peninsula Hospitals
Burlingame, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
City of Hope
Duarte, California
Northbay Cancer Center
Fairfield, California
Kaiser Permanente, Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
California Cancer Center - North Fresno
Fresno, California
Cancer Care Associates
Fresno, California
California Cancer Care - Greenbrae
Greenbrae, California
Sutter Health Western Division Cancer Research Group
Greenbrae, California
Kaiser Permanente, Hayward
Hayward, California
Saint Rose Hospital
Hayward, California
Loma Linda University Medical Center
Loma Linda, California
University of Southern California
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Community Hospital of Monterey Peninsula
Monterey, California
El Camino Hospital
Mountain View, California
Showing 40 of 894 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.